Latest Intelligence on Therapy Area in Norway

Select information type

Refine your search

Search tips

Published within

« | 1 | » »|

Type Product title / description Pub Price

Algeta: Alpharadin clears hurdle but more to come

Algeta has announced that Apharadin met its primary endpoint in a bone marker analysis in a phase II hormone-refractory prostate cancer trial, demonstrating its potential in bone metastases. However, this must be translated into survival and/or quality-of-life advantage to guarantee a successful launch. Algeta must also find a suitable marketing partner to bring the product to the market.

Published By Datamonitor
27 Feb 2006

« | 1 | » »|

No help is available.